We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Hah! Just kidding… But did you think, “Oh no!” or “Yippee!” when you saw that subject line? The ups and downs of the Consumer ...

Q3 2025 Management View NGL Energy Partners executed several strategic initiatives in Q3, including the sale of 17 natural gas liquids terminals and an additional Green Bay terminal, generating total ...

i3 Verticals, Inc. (NASDAQ: IIIV) Q1 2025 Earnings Call Transcript February 7, 2025 ...

Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Acadian Asset Management Incorporated Earnings Conference Call and Webcast for the Fourth Quarter 2024.

Q4 2024 Earnings Call Transcript February 11, 2025 Operator: Welcome to Watts Water Technologies, Inc. Fourth Quarter and ...

Barrick has completed a comprehensive feasibility study for the Super Pit Expansion at Lumwana in Zambia25, transforming the ...

OGI earnings call for the period ending December 31, 2024. Organigram ( OGI -13.84%) Q1 2025 Earnings Call Feb 11, 2025, 8:00 ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...

Financial discipline remained a priority, with approximately $1.1 billion of the targeted $1.5 billion in savings already realized. The company has identified an additional $2 billion in savings, with ...